Less than a year after Traversa Therapeutics declared bankruptcy, the company's founders are making another run at the RNAi drugs space in the form of startup Solstice Biologics, which announced this week that it has raised $18 million in a Series A round of financing.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Browse our free articlesYou can still register for access to our free content.